New Zealand biotechnology company developing immunotherapeutics to address chronic periodontal disease in companion animals
New Zealand biotechnology company developing immunotherapeutics to address chronic periodontal disease in companion animals. Its veterinary treatment is intended to target underlying disease drivers and improve dental health and immune response; the company is advancing canine clinical development and manufacturing toward USDA licensure.